Medtronic Inc (MDT)

Experts have mixed opinions on Medtronic Inc (MDT-N), with one reviewing it positively, stating that the company is set to capitalize on advancements in AI, alongside the strong market demographics of the Baby Boomer population. The other expert, however, is more skeptical, acknowledging that while MDT is making gains against competitors like Boston Scientific, it lacks the substantial R&D capabilities necessary for sustained leadership in the long run. There is caution expressed that the investment may not be suitable for those looking for a long-term hold, as the focus is more on trading amidst anticipated product launches that could support the stock's upward movement for up to 18 months. Ultimately, while MDT may have a diversified product range which provides some advantage, the lack of a strong R&D pipeline compared to its peers raises concerns about its future competitiveness.